Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 465

Sort by

Sort Order Select

Journal Articles

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms

Hans Carl Hasselbalch, Margitta Elvers, Andrew I. Schafer

Blood (2021) 137 (16): 2152–2160.

https://doi.org/10.1182/blood.2020008109

Published: 2021

Journal Articles

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Jessica L. Bridgford, Su Min Lee, Christine M. M. Lee, Paola Guglielmelli, Elisa Rumi, Daniela Pietra, Stephen Wilcox, Yash Chhabra, Alan F. Rubin, Mario Cazzola, Alessandro M. Vannucchi, Andrew J. Brooks, Matthew E. Call, Melissa J. Call

Blood (2020) 135 (4): 287–292.

https://doi.org/10.1182/blood.2019002561

Published: 2020

Includes: Supplemental data

Journal Articles

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

Olivier Mansier, Badr Kilani, Amélie V. Guitart, Alexandre Guy, Virginie Gourdou-Latyszenok, Caroline Marty, Marie Parrens, Isabelle Plo, William Vainchenker, Chloé James

Blood (2019) 134 (26): 2383–2387.

https://doi.org/10.1182/blood.2019001163

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

Jie Bai, MD, Yuhui Zhang, Yingshao Wang, Guangshuai Teng, Yan Wang, Chenxiao Du, Yafang Chen, Huiqin Zhang, Yanqi Li, Lixia Fu, Lei Zhang, MD, Yuan Zhou, PhD

Blood (2019) 134 (Supplement_1): 1149.

https://doi.org/10.1182/blood-2019-125429

Published: 2019

Journal Articles

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

Joseph Tripodi, Douglas Tremblay, MD, Ronald Hoffman, MD, Umut Ozbek, PhD, John Mascarenhas, MD, Marina Kremyanskaya, Vesna Najfeld, PhD

Blood (2019) 134 (Supplement_1): 1687.

https://doi.org/10.1182/blood-2019-128948

Published: 2019

Journal Articles

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

Bruno Kosa Lino Duarte, Stephanie Ospina-Prieto, PhD, Lucia Helena Siqueira, Jessica O F Guanaes, MSc, Fernando Ferreira Costa, MD PhD, Margareth C Ozelo, MD PhD

Blood (2019) 134 (Supplement_1): 3618.

https://doi.org/10.1182/blood-2019-131488

Published: 2019

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Tobias Ronny Haage, MD, Andreas Johann Müller, Priyadharshini Arunachalam, Thomas Fischer, MD

Blood (2019) 134 (Supplement_1): 2965.

https://doi.org/10.1182/blood-2019-122660

Published: 2019

Journal Articles

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

Yoshinori Ozono, MD, Kotaro Shide, MD PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Yuki Tahira, MD, Masaaki Sekine, MD, Keiichi Akizuki, MD, Kenichi Nakamura, MD, Hisayoshi Iwakiri, MD, Tomonori Hidaka, MD, Yoko Kubuki, MD PhD, Satoru Hasuike, MD PhD, Fumiyo Toyoshima, MD PhD, Akira Sawaguchi, MD PhD, Kenji Nagata, MD PhD, Kazuya Shimoda, MD PhD

Blood (2019) 134 (Supplement_1): 310.

https://doi.org/10.1182/blood-2019-130042

Published: 2019

Journal Articles

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Tatiana V Makarik, PhD, Adhamjon O Abdullaev, MD PhD, Sergei M. Kulikov, PhD, Elena E Nikulina, Svetlana A Treglazova, Irina N Subortseva, MD, Alla M. Kovrigina, MD PhD, Anait L. Melikyan, MD PhD, Andrey B Sudarikov, PhD DSc, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5400.

https://doi.org/10.1182/blood-2019-124767

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Andrew Sochacki, MD, Shilin Zhao, PhD, Cosmin Adrian Bejan, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1203.

https://doi.org/10.1182/blood-2019-129639

Published: 2019

Journal Articles

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Blood (2019) 134 (Supplement_1): 4171.

https://doi.org/10.1182/blood-2019-126980

Published: 2019

Journal Articles

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Maria Zingariello, PhD, Vittorio Rosti, MD, Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD PhD, Claudio Bardelli, PhD, Maria Mazzarini, Rosa Alba Rana, Giovanni Barosi, Anna Rita Rita Migliaccio, PhD

Blood (2019) 134 (Supplement_1): 4209.

https://doi.org/10.1182/blood-2019-123140

Published: 2019

Journal Articles

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469-479.

Blood (2019) 134 (14): 1195.

https://doi.org/10.1182/blood.2019002756

Published: 2019

Journal Articles

Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2 V617F provide a therapeutic target of elotuzumab

Blood (2019) 134 (10): 814–825.

https://doi.org/10.1182/blood.2019000051

Published: 2019

Includes: Supplemental data

Journal Articles

Oral idasanutlin in patients with polycythemia vera

John Mascarenhas, Min Lu, Heidi Kosiorek, Elizabeth Virtgaym, Lijuan Xia, Lonette Sandy, Ruben Mesa, Bruce Petersen, Noushin Farnoud, Vesna Najfeld, Raajit Rampal, Amylou Dueck, Ronald Hoffman

Blood (2019) 134 (6): 525–533.

https://doi.org/10.1182/blood.2018893545

Published: 2019

Includes: Supplemental data

NARROW

The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms

Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning

Description of a knock-in mouse model of JAK2 V617F MPN emerging from a minority of mutated hematopoietic stem cells

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs)

The Pro-Adhesive and Reduced Angiogenic Properties of Endothelial Colony Forming Cells (ECFC) from JAK2 V617F MPN Patients Are Not Related to the Expression of the JAK2 mutation in These Cells: A Potential Role of ADAM17

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Reveal the Neutrophil: Elucidating the Role of a Neutrophil-Specific JAK2-V617F Mutation

Depletion of Neoplastic CD11b Positive Cells in Jak2 V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis

The Frequency of Calr and MPL Gene Mutations in Jak2 V617F - Positive Chronic Myeloproliferative Neoplasms in Russia

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Clinical Characteristics and Cardioavscular Events in Patients with Esential Thrombocythemia with <10% Vs. ≥10% JAK2 V617F Allele Burden

Shared and Distinctive Ultrastructural Abnormalities Expressed By Megakaryocytes in Bone Marrow and Spleen from Patients with Primary Myelofibrosis

Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469-479.

Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2 V617F provide a therapeutic target of elotuzumab

Oral idasanutlin in patients with polycythemia vera

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only